Clover Corporation (ASX:CLV) disclosed full-year revenue of $97.4 million for FY26, representing a 13% increase on the prior year, and a net profit after tax of $10.5 million, up from $7.0 million in FY25, according to the Chairman's Address delivered at the company's Annual General Meeting on 17 November 2026.

Key Points

  • FY26 revenue rose 13% to $97.4 million, driven by demand for micro-encapsulated powders and product mix diversification
  • Full-year NPAT reached $10.5 million, compared with $7.0 million in FY25
  • The Board declared a 1.25 cents final dividend for FY26
  • Chairman Rupert Harrington retired at the close of the AGM, with Ian Glasson succeeding him as Chairman

FY26 Financial Results and Gross Margin Performance

Clover Corporation reported FY26 revenue of $97.4 million, a 13% increase on the prior year, with the result attributed to demand for the company's micro-encapsulated powders and diversification of its product mix and supply chains. NPAT for the full year was $10.5 million, compared with $7.0 million in FY25. According to the filing, gross margin improvement was driven by higher-value products resulting from the company's research and development programs, as well as manufacturing performance at Melody Dairies and the continued integration of its Ecuador oil facility.

Revenue Diversification and CholineXcel Growth Pathway

The filing states that second-half FY26 revenue was underpinned by stronger demand for microencapsulated ARA (arachidonic acid – omega 6) powders, with the company noting that global infant formula markets continue to be constrained by low birth rates. Revenue diversification is progressing, supported by customers supplying demand from older populations seeking clean-label, science-backed nutrition products. The filing also states that CholineXcel remains a core growth opportunity and is expected to provide a foundation for growth in FY28 and beyond, with management evaluating options to secure additional spray drying capacity.

Board Succession and Development Committee Activities

Chairman Rupert Harrington retired as a director and Chairman at the close of the AGM, with Ian Glasson assuming the chairmanship. The filing states that planned succession changes to the Board and Committees had been previously communicated. The Development and Innovation Committee, established in the prior calendar year, includes advisors Professor Colin Barrow and Dr Efi Farmakalidis. The company also disclosed it is continuing to investigate the development of a proprietary range of science-backed products using its encapsulated powders in the nutraceutical sector, with resources allocated to support that initiative.